What Wyss Center does

The Wyss Center for Bio and Neuroengineering is a Swiss not-for-profit foundation established in 2014 by philanthropist Hansjörg Wyss with an initial contribution of approximately 100 million CHF and headquartered at Campus Biotech in Geneva. The Center translates neurotechnology research into clinical applications targeting the more than 3 billion people worldwide affected by neurological and mental health disorders, spanning amyotrophic lateral sclerosis, epilepsy, dementia, spinal cord injury, stroke, and psychiatric conditions. It employs 101-250 staff and operates across core programs in brain-computer interfaces, intraoperative imaging, neuromodulation, and AI-guided diagnostics.

The Center's technology portfolio includes ABILITY Neurotech's fully implantable wireless optical-link electrocorticography BCI with a sub-5mm implant and 50 Mbps laser-based data transmission; Clee Medical's Neuro Access ultra-high-resolution OCT imaging at 30 micrometers plus its Clee convection-enhanced drug delivery system; BrainQuant's AI-powered ASL MRI analysis for early dementia detection; dEEGtal Insights' automated EEG analysis for epilepsy diagnosis; Dandelion Science's generative AI neuromodulation platform; DataFlight Solutions' microscopy data infrastructure handling 400 TB/day; and Epios (BrainScape Medical) long-term brain monitoring and neurostimulation. These programs are supported by 150+ collaborations with partners including EPFL, Geneva University Hospitals, University of Geneva, CHUV, University Medical Center Utrecht, Johns Hopkins, and Mila, plus a 1,000 m² AI Health Hub inaugurated at Campus Biotech in December 2025.

The Wyss Center's business model is venture creation rather than direct product sales: it funds internal research, validates technologies clinically, then spins out independent companies that license the underlying IP and raise third-party capital. Foundation operations are underwritten by philanthropic funding (primarily from Hansjörg Wyss), research grants, and licensing returns. Under Prof. Dr. Erwin Böttinger's tenure (April 2023 to July 2026), the Center spun off six companies in two years; Dr. Tracy Laabs, founding Deputy Director since 2015, succeeds him as Director effective July 1, 2026.

Name

Wyss Center

Legal name

Wyss Center for Bio and Neuroengineering

Website

https://wysscenter.ch

Company type

Private

Founded year

2014

Operating status

Operating

Headcount range

101–250 employees

Short description

The Wyss Center for Bio and Neuroengineering is a Geneva-based not-for-profit foundation that translates neuroscience research into clinical neurotechnologies. It develops brain-computer interfaces, AI-powered diagnostics, and neuromodulation platforms, commercializing them through spin-off companies serving patients with neurological and mental health disorders.

Ownership category

akta.pro rank

Product category

Neurotechnology Research and Bioengineering

NAICS

Research and Development in the Physical, Engineering, and Life Sciences (54171), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)

SIC

Services-Commercial Physical & Biological Research (8731), Electromedical & Electrotherapeutic Apparatus (3845), Services-Medical Laboratories (8071)

akta.pro primary industry

Scientific Data Management & Data Platforms (SDMS/Data Lakehouse for R&D) (HLAGAJAC)

akta.pro secondary industries

Bioinformatics, Multi-Omics Data Analysis & Interpretation Services (HLAGANAI), Neurodiagnostic Centers (EEG/EMG/NCS) (HLAFAKAK), Biosensors & Lab-on-Chip (BioMEMS) (HDAHALAK)

Keywords

• Neurotechnology research
• Brain-computer interfaces
• AI healthcare solutions
• Venture building services
• Biomedical engineering

Headquarters

HQ city

Geneva

HQ country

Switzerland

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Infrastructure

Revenue model

1. Philanthropic Funding: Primary funding from philanthropist Hansjörg Wyss and other donors supporting the foundation's mission to accelerate neurotechnology development
2. Venture Building Revenue: Revenue generated through spin-off companies (ABILITY Neurotech, Clee Medical, BrainQuant, dEEGtal Insights, Dandelion Science, DataFlight Solutions) that commercialize developed technologies
3. Research Partnerships: Collaborative research projects with academic and clinical partners funded by grants and institutional partnerships

Go-to-market motion1 record

Distribution channels1 record

Marketing channels6 records

Core offering

The Wyss Center is a not-for-profit research and development foundation that develops neurotechnologies and bioengineering solutions—including brain-computer interfaces, intraoperative imaging, AI-powered diagnostics, and neuromodulation platforms—and commercializes them by spinning off dedicated companies. Its portfolio spans tools for neurosurgery, brain monitoring, dementia and epilepsy detection, and large-scale biomedical data handling, delivered through subsidiaries such as Clee Medical, ABILITY Neurotech, BrainQuant, dEEGtal Insights, DataFlight Solutions, and Dandelion Science.

Product overview

The Wyss Center operates as a neurotechnology research and venture-building organization that has developed a portfolio of spin-off companies and research platforms. The core product offerings include Neuro Access and Clee (from Clee Medical) for precision neurosurgery with OCT imaging and drug delivery; the ABILITY BCI System for fully implantable brain-computer interfaces; BrainQuant for AI-powered early dementia detection via ASL MRI; dEEGtal Insights for automated EEG analysis in epilepsy diagnosis; DataFlight Solutions for big microscopy data handling; Dandelion Science for generative AI neuromodulation therapies; and Epios for brain monitoring and neurostimulation. These products are organized around the Wyss Center's AI Hub infrastructure, which provides the foundational AI integration capabilities for healthcare and neurotechnology applications. The center acts as both an incubator for these technologies and a provider of research capabilities through its facilities and partnerships.

Differentiator

Problem solved

Functional benefit

Products and services

• Neuro Access A minimally invasive robot-assisted surgical tool integrating ultra-high-resolution Optical Coherence Tomography (OCT) imaging with AI-powered navigation to provide real-time intraoperative visualization of brain structures and blood vessels during neurosurgery at 30μm resolution, for neurosurgeons and hospitals.
• Clee A single-use disposable solution for accurate convection-enhanced delivery (CED) of biologics and drugs into the brain, designed to prevent fluid backflow and operate without MR equipment, for neurosurgeons and hospitals performing targeted drug delivery.
• ABILITY BCI System A fully implantable wireless optical-link electrocorticography (ECoG) brain-computer interface system with a sub-5mm implant and 50 Mbps laser-based data transmission, designed to restore communication, movement, and independence for patients with severe neurological impairment such as ALS, targeted at clinical research centers and ultimately patients with paralysis.
• BrainQuant A smart software platform for non-invasive, early detection of dementia using Arterial Spin Labeling (ASL) MRI sequences processed with AI algorithms to detect cognitive decline before symptoms, eliminating radiation exposure and FDG-PET scans, for radiologists, neurologists, and memory clinics.
• dEEGtal Insights AI-powered EEG analysis platform delivering automated medical reporting, automatic slowing detection, and comprehensive EEG signal overview for early epilepsy diagnosis, for neurologists, epileptologists, and hospitals.
• DataFlight Solutions Next-generation data platform for scalable storage, visualization, and analysis of large high-throughput 3D fluorescence microscopy data, adapting image resolution based on information content to achieve 10x faster and more efficient data handling, for biomedical researchers and imaging core facilities.
• Dandelion Science A generative neuromodulation platform that uses generative AI to synthesize precision sensory stimulation therapies on demand for non-invasive treatment of neurodegenerative and neuropsychiatric disorders, for neurology and psychiatry clinics and research centers.
• Epios Long-term brain monitoring and neurostimulation technology designed to detect seizure precursors and deliver responsive neurostimulation, granted FDA Breakthrough Device Designation for patients with infrequent seizure episodes and pharmacoresistant epilepsy, for epilepsy monitoring centers and neurology hospitals.
• AI Hub AI-driven health hub at Campus Biotech integrating AI into healthcare for neurological and psychiatric treatments across four missions: patient care, translational research, AI integration in healthcare operations, and education, for clinical researchers, clinicians, and healthcare innovators.

Quantifiable outcome

• 6 companies spun off in 2 years
• +4 more outcomes

Named customers4 records

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability9 records

Feature6 records

Partnerships

18 partnerships are on record, tiered major, core and supporting.

• Bio-TechnemajorStrategic or Co-development Partner · 11 December 2025Strategic collaboration to develop automated workflow for RNA and protein detection in 3D tissue specimens, extending spatial biology capabilities for drug discovery and diagnostic development.
• Foundation Campus Biotech GenevacoreStrategic or Co-development PartnerThe Wyss Center is based at Campus Biotech, a major innovation campus in Geneva. This co-location enables close collaboration and resource sharing among neurotechnology researchers and companies.
• EPFL (École Polytechnique Fédérale de Lausanne)coreStrategic or Co-development PartnerEPFL researchers collaborate on neuroprosthetics, brain-computer interfaces, and neurotechnology projects. The partnership brings together world-class engineering and neuroscience expertise.
• Geneva University Hospitals (HUG)coreStrategic or Co-development PartnerClinical partnership for testing and validating neurotechnologies with real patients. HUG provides clinical expertise and patient access for research trials.
• University of GenevacoreStrategic or Co-development PartnerAcademic partnership with leading neuroscience researchers including the Synapsy Centre for Neuroscience and Mental Health for fundamental research collaboration.
• Lausanne University Hospital (CHUV)majorStrategic or Co-development PartnerCollaboration with CHUV for neuroscience research and clinical applications, particularly in neuroprosthetics and rehabilitation.
• University Medical Center UtrechtmajorStrategic or Co-development PartnerLeading European BCI center conducting clinical trials for ABILITY Neurotech's brain-computer interface. Part of the INTRECOM consortium.
• UTMB (University of Texas Medical Branch)majorStrategic or Co-development PartnerPartnership to advance neuroscience research and technologies, including collaboration with the Moody Brain Health Institute.
• Swiss Center for Electronics and Microtechnology (CSEM)supportingTechnology or IntegrationTechnical collaboration for electronics and microtechnology development supporting neurotechnology devices.
• ONWARD MedicalsupportingTechnology or IntegrationCollaboration in the field of spinal cord stimulation and brain-spine interfaces for movement restoration.
• CorTecsupportingTechnology or IntegrationTechnology partnership for brain-computer interface components, including electrode systems and neural recording technology.
• MILA (Quebec Artificial Intelligence Institute)supportingTechnology or IntegrationAI collaboration for developing machine learning algorithms for neural signal analysis and neurotechnology applications.
• Johns Hopkins Medicine, Applied Physics Laboratory, and UniversitymajorStrategic or Co-development PartnerComprehensive partnership across Johns Hopkins institutions for neuroscience research and neurotechnology development.
• FONGITsupportingStrategic or Co-development PartnerGeneva-based innovation foundation supporting Clee Medical and other neurotech startups with expertise and resources.
• Medical University of GrazsupportingStrategic or Co-development PartnerAcademic partner in Austria for BCI research and clinical evaluation programs.
• Technical University of MunichsupportingStrategic or Co-development PartnerParallel intra-operative evaluation programs for ABILITY Neurotech's BCI system.
• Graz University of TechnologysupportingStrategic or Co-development PartnerTechnical university partnership for neurotechnology development and testing.
• Hôpital National de la Vision 15-20supportingStrategic or Co-development PartnerPartnership for vision-related neurotechnology research and applications.

Scale indicators9 records

Recent moves10 records

Expansion highlights6 records

Direct peers

• Synchron: Implantable BCI company pursuing first-in-human chronic implants for communication restoration in ALS patients. Competes head-to-head with the Wyss Center's ABILITY platform for clinical trial positioning and eventual payer adoption.
• Precision Neuroscience: Cortical-interface developer focused on high-resolution, minimally invasive neural recording for paralysis and speech restoration. Direct competitor to the Wyss Center's BCI portfolio in the high-bandwidth communication market.
• Neuralink: Develops high-bandwidth implantable brain-computer interfaces for paralysis and neurological disorders. Directly competes with ABILITY Neurotech (Wyss Center spin-off) on chronic implant safety, bandwidth, and surgical approach.
• Blackrock Neurotech: Utah-array-based BCI pioneer with extensive human clinical trial history in motor and speech restoration. Overlaps directly with the Wyss Center's ABILITY Neurotech mission of high-bandwidth communication for paralyzed patients.
• Howard Hughes Medical Institute (Janelia Research Campus): Philanthropically funded neuroscience research campus with similar mission of building tools and technologies to understand the brain. Comparable translational model that produces both academic research and enabling technologies for the broader neuroscience community.
• Allen Institute for Brain Science: Non-profit neuroscience research organization conducting large-scale brain mapping and neurotechnology development, with a similar translational mission and philanthropic funding model. Operates as a comparable brain-science research foundation producing tools and datasets used across academia and industry.
• Paradromics: High-data-rate neural interface company building microscale electrode arrays for speech and motor BCIs. Competes on bandwidth and chronic implant scalability with ABILITY Neurotech's optical-link ECoG approach.
• ONWARD Medical: Listed partner of the Wyss Center developing spinal cord stimulation and brain-spine interfaces for movement restoration in spinal cord injury. Overlaps in neuromodulation hardware and clinical pathway navigation.

Broad incumbents

• Max Planck Institute for Neuroscience: Large-scale publicly funded neuroscience research network with deep bench strength in brain physiology, imaging, and computation. Comparable in scientific depth but operates on a government-funded, multi-institute model rather than venture-creation.
• Salk Institute for Biological Studies: Independent non-profit biological research organization with strong neuroscience portfolio and founder/philanthropy-driven model. Comparable institutional structure and translational science orientation, though with broader biological scope.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• YouTubeyoutube.com/@WyssCenterGeneva
• LinkedInlinkedin.com/company/wyss-center-for-bio-and-neuroengineering
• Instagraminstagram.com/wyss.center
• Xx.com/wysscenter
• Facebookfacebook.com/wysscenter

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Subsidiaries6 records

Funding overview

Funding rounds3 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments5 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Wyss Center